Mesoblast Limited (ASX:MSB) Disc Repair Results Highlighted At Key Orthopaedic Conference

Melbourne, Sep 15, 2009 AEST (ABN Newswire) - Mesoblast Limited's (ASX:MSB)(PINK:MBLTY) successful preclinical disc repair trial was featured at the World Congress on Osteoarthritis held in Montreal, Canada, over the weekend.

More than 1,000 specialists in orthopaedics and rheumatology, as well as pain doctors and clinical scientists attended the prestigious congress conducted by the OsteoArthritis Research Society International (OARSI).

Internationally recognised cartilage expert, Professor Peter Ghosh, discussed how a single low-dose injection of Mesoblast's allogeneic or "off-the-shelf" adult stem cells into severely damaged intervertebral discs resulted in dramatic reversal of the degenerative process, regrowth of disc cartilage, and sustained normalisation of disc pathology, anatomy and function.

Mesoblast will continue to ensure that its achievements are highlighted and recognised at respected international conferences and meetings attended by key opinion leaders.

For the complete Mesoblast ASX Announcement and Professor Ghosh's presentation, please click the link below:

http://www.abnnewswire.net/media/en/docs/61430-ASX-MSB-323978.pdf

Contact

Julie Meldrum Corporate Communications Director Mesoblast Limited Tel: +61-3-9639-6036 Mob: +61-419-228-128 Email: julie.meldrum@mesoblast.com www.mesoblast.com